Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Teriflunomide
Drug ID BADD_D02165
Description Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Indications and Usage Used in the treatment of relapsing forms of multiple sclerosis (MS).
Marketing Status approved
ATC Code L04AA31
DrugBank ID DB08880
KEGG ID D10172
MeSH ID C527525
PubChem ID 54684141
TTD Drug ID Not Available
NDC Product Code 47621-049; 51991-882; 58468-0211; 59651-054; 62332-314; 69339-169; 70377-017; 70710-1114; 12579-185; 12579-190; 59651-036; 65727-058; 0378-0628; 69238-1303; 69238-1304; 51991-881; 0480-3157; 69539-315; 69539-316; 70512-851; 66499-0059; 16729-400; 70710-1115; 70771-1011; 53747-061; 66039-916; 59651-055; 0378-0627; 70771-1010; 59285-001; 63850-8081; 69037-0016; 16729-399; 46708-314; 0480-3156; 69339-170; 69539-033; 70377-018; 12579-191; 42291-831; 60505-4478; 69025-129; 69025-130; 69539-032; 31722-247; 46708-313; 62332-313; 12579-186; 14501-0086; 17337-0070; 43598-281; 43598-282; 60505-4477; 68462-423; 68462-424; 0781-5747; 0781-5755; 31722-246; 42291-830; 58468-0210
UNII 1C058IKG3B
Synonyms teriflunomide | (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | (2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide | RS 61980 | Aubagio | HMR1726 | HMR-1726 | A 771726 | A 1726 | A771726 | A-771726 | A77 1726
Chemical Information
Molecular Formula C12H9F3N2O2
CAS Registry Number 163451-81-8
SMILES CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anorectal discomfort07.03.03.0030.000820%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.016--
Bladder dysfunction20.03.03.0020.000820%Not Available
Upper-airway cough syndrome22.12.03.0360.000820%
Functional gastrointestinal disorder07.11.01.0160.003761%Not Available
Slow speech19.19.02.004; 17.02.08.0160.000820%Not Available
Intraductal proliferative breast lesion21.05.01.014; 16.10.01.0060.000362%Not Available
Faeces soft07.01.03.0080.002291%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000772%Not Available
Invasive breast carcinoma21.05.01.013; 16.10.01.0050.000241%Not Available
Anal incontinence17.05.01.021; 07.01.06.0290.006341%
Frustration tolerance decreased19.04.02.0160.001712%Not Available
Abnormal loss of weight14.03.02.0190.000651%Not Available
Alopecia areata23.02.02.008; 10.04.02.0110.000530%Not Available
Coeliac disease10.04.04.012; 07.17.01.008; 14.02.01.0070.000362%Not Available
Fallopian tube cancer21.11.01.009; 16.12.07.0010.000241%Not Available
Hilar lymphadenopathy22.09.03.005; 01.09.01.0230.000241%Not Available
Lateral medullary syndrome24.04.06.038; 17.08.01.0550.000241%Not Available
Leiomyosarcoma16.33.07.001; 15.09.03.0160.000241%Not Available
Lichen sclerosus23.03.08.006; 21.10.03.0100.001230%Not Available
Lung adenocarcinoma22.08.01.007; 16.19.01.0020.000241%Not Available
Metastases to lymph nodes01.09.01.015; 16.22.02.0060.000362%Not Available
Overweight14.03.02.0210.000241%Not Available
Post-traumatic stress disorder19.06.06.0020.000241%Not Available
Slow response to stimuli17.02.05.0630.000241%Not Available
Teeth brittle07.09.05.0150.000820%Not Available
Progressive multiple sclerosis17.16.01.0060.000844%Not Available
IIIrd nerve paresis17.04.02.006; 06.05.02.0190.000241%Not Available
Splenic lesion01.09.02.0170.000241%Not Available
The 18th Page    First    Pre   18 19 20    Next   Last    Total 20 Pages